Skip to main content

Table 4 HPV prevalence and distribution of high risk and low risk genotypes across cytological findings

From: Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria

 

PAP positive

PAP negative

(PAP III+) (n = 21)

(PAP I-II) (n = 363)

Age, years

32.6 (8.1)

35.9 (11.5)

Mean (SD)

Age at firts sexual contact, years

16.8 (2.8)

16.8 (2.4)

Mean (SD)

BMI, Mean (SD)

22.5 (3.3)

23.4 (4.0)

Current smoker, n (%)

14 (66.7)

117 (32.5)*

HPV positive, n (%)

19 (90.5)

75 (20.7)*

Multiple HPV infection, n (%)

7 (33.3)

33 (9.1)*

Nonavalent type HrHPV, n (%)a

15 (71.4)

48 (13.2)*

HPV 16, n (%)

9 (45)

20 (5.8)*

HPV 18, n (%)

2 (9.5)

4 (1.1)*

HPV 31, n (%)

1 (4.8)

13 (3.6)

HPV 33, n (%)

1 (4.8)

14 (3.9)

  1. SD standard deviation, HrHPV high risk HPV genotypes
  2. PAP III + abnormal PAPanicolaou (cervical smear cytology) including PAP III, PAP IIID, PAP IVA and IVB and PAP V
  3. PAPI-II normal PAPanicolaou (cervical smear cytology)
  4. *P = sig
  5. a16, 18, 31, 33, 45, 52 58 (all HrHPV types included in nonavalen HPV vaccine)